Serotonin regulates osteoblast proliferation and function in vitro

Brazilian Journal of Medical and Biological Research

Volumn 47, Issue 9, 2014, Pages 759-765

  Dai, S Q ^a   Yu, L P ^a   Shi, X ^b   Wu, H ^c   Shao, P ^a   Yin, G Y ^a   Wei, Y Z ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c SOOCHOW UNIVERSITY   (China)

Author keywords

5 HT; 5 HT receptors; Differentiation; Osteoblast; Proliferation; Serotonin

Indexed keywords

ALKALINE PHOSPHATASE; OSTEOCALCIN; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; PRIMER DNA; SEROTONIN RECEPTOR;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MINERALIZATION; NONHUMAN; OSTEOBLAST; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BONE MINERALIZATION; CYTOLOGY; DRUG EFFECTS; METABOLISM; PRIMARY CELL CULTURE; SPRAGUE DAWLEY RAT;

ANIMALS; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA PRIMERS; GENE EXPRESSION; OSTEOBLASTS; PRIMARY CELL CULTURE; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, SEROTONIN; SEROTONIN;

EID: 84906519474     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20143565     Document Type: Article

References (39)

1. Anastasilakis AD, Polyzos SA, Delaroudis S, Bisbinas I, Sakellariou GT, Gkiomisi A, et al. The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass. Clin Endocrinol 2012; 77: 816-822, doi: 10.1111/j.1365-2265.2012.04459.x.
2. Cutler GB Jr. The role of estrogen in bone growth and maturation during childhood and adolescence. J Steroid Biochem Mol Biol 1997; 61: 141-144, doi: 10.1016/S0960-0760(97)80005-2.
3. Somjen D. Vitamin D modulation of the activity of estrogenic compounds in bone cells in vitro and in vivo. Crit Rev Eukaryot Gene Expr 2007; 17: 115-147, doi: 10.1615/CritRevEukarGeneExpr.v17.i2.30.
4. Vescini F, Grimaldi F. PTH 1-84: bone rebuilding as a target for the therapy of severe osteoporosis. Clin Cases Miner Bone Metab 2012; 9: 31-36.
5. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 85-102, doi: 10.1016/S0278-5846(02)00338-X.
6. Ambrosini P.J. A review of pharmacotherapy of major depression in children and adolescents. Psychiatr Serv 2000; 51: 627-633, doi: 10.1176/appi.ps.51.5.627.
7. Kastelic EA, Labellarte MJ, Riddle M.A. Selective serotonin reuptake inhibitors for children and adolescents. Curr Psychiatry Rep 2000; 2: 117-123, doi: 10.1007/s11920-000-0055-x.
8. Ryan N.D. Medication treatment for depression in children and adolescents. CNS Spectr 2003; 8: 283-287.
9. Bolton JM, Metge C, Lix L, Prior H, Sareen J, Leslie W.D. Fracture risk from psychotropic medications: a populationbased analysis. J Clin Psychopharmacol 2008; 28: 384-391, doi: 10.1097/JCP.0b013e31817d5943.
10. Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte J.A. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry 2010; 71: 338-347, doi: 10.4088/JCP.08m04595gre.
11. Diem SJ, Blackwell TL, Stone KL, Yaffe K, Haney EM, Bliziotes MM, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007; 167: 1240-1245, doi: 10.1001/archinte.167.12.1240.
12. Lewis CE, Ewing SK, Taylor BC, Shikany JM, Fink HA, Ensrud KE, et al. Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res 2007; 22: 211-219, doi: 10.1359/jbmr.061017.
13. Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998; 351: 1303-1307, doi: 10.1016/S0140-6736(97)09528-7.
14. Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007; 167: 188-194, doi: 10.1001/archinte.167.2.188.
15. Vestergaard P, Rejnmark L, Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int 2008; 82: 92-101, doi: 10.1007/s00223-007-9099-9.
16. Ziere G, Dieleman JP, van der Cammen TJ, Hofman A, Pols HA, Stricker B.H. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 2008; 28: 411-417, doi: 10.1097/JCP.0b013e31817e0ecb.
17. Battaglino R, Fu J, Spate U, Ersoy U, Joe M, Sedaghat L, et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 2004; 19: 1420-1431, doi: 10.1359/JBMR.040606.
18. Bliziotes MM, Eshleman AJ, Zhang XW, Wiren K.M. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 2001; 29: 477-486, doi: 10.1016/S8756-3282(01)00593-2.
19. Westbroek I, van der Plas A, de Rooij KE, Klein-Nulend J, Nijweide P.J. Expression of serotonin receptors in bone. J Biol Chem 2001; 276: 28961-28968, doi: 10.1074/jbc.M101824200.
20. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008; 135: 825-837, doi: 10.1016/j.cell.2008.09.059.
21. Baudry A, Bitard J, Mouillet-Richard S, Locker M, Poliard A, Launay JM, et al. Serotonergic 5-HT(2B) receptor controls tissue-nonspecific alkaline phosphatase activity in osteoblasts via eicosanoids and phosphatidylinositol-specific phospholipase C. J Biol Chem 2010; 285: 26066-26073, doi: 10.1074/jbc.M109.073791.
22. Collet C, Schiltz C, Geoffroy V, Maroteaux L, Launay JM, de Vernejoul M.C. The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation. FASEB J 2008; 22: 418-427, doi: 10.1096/fj.07-9209com.
23. Cui Y, Niziolek PJ, MacDonald BT, Zylstra CR, Alenina N, Robinson DR, et al. Lrp5 functions in bone to regulate bone mass. Nat Med 2011; 17: 684-691, doi: 10.1038/nm.2388.
24. Gustafsson BI, Westbroek I, Waarsing JH, Waldum H, Solligard E, Brunsvik A, et al. Long-term serotonin administration leads to higher bone mineral density, affects bone architecture, and leads to higher femoral bone stiffness in rats. J Cell Biochem 2006; 97: 1283-1291, doi: 10.1002/jcb.20733.
25. Hirai T, Tokumo K, Tsuchiya D, Nishio H. Expression of mRNA for 5-HT2 receptors and proteins related to inactivation of 5-HT in mouse osteoblasts. J Pharmacol Sci 2009; 109: 319-323, doi: 10.1254/jphs.08243SC.
26. Locker M, Bitard J, Collet C, Poliard A, Mutel V, Launay JM, et al. Stepwise control of osteogenic differentiation by 5-HT(2B) receptor signaling: nitric oxide production and phospholipase A2 activation. Cell Signal 2006; 18: 628-639, doi: 10.1016/j.cellsig.2005.06.006.
27. Modder UI, Achenbach SJ, Amin S, Riggs BL, Melton LJ III, Khosla S. Relation of serum serotonin levels to bone density and structural parameters in women. J Bone Miner Res 2010; 25: 415-422, doi: 10.1359/jbmr.090721.
28. Yin Z, Chen X, Chen JL, Shen WL, Hieu Nguyen TM, Gao L, et al. The regulation of tendon stem cell differentiation by the alignment of nanofibers. Biomaterials 2010; 31: 2163-2175, doi: 10.1016/j.biomaterials.2009.11.083.
29. Schmittgen TD, Zakrajsek B.A. Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. J Biochem Biophys Methods 2000; 46: 69-81, doi: 10.1016/S0165-022X(00) 00129-9.
30. Bliziotes M, Eshleman A, Burt-Pichat B, Zhang XW, Hashimoto J, Wiren K, et al. Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone 2006; 39: 1313-1321, doi: 10.1016/j.bone.2006.06.009.
31. Nakano Y. Novel function of DUSP14/MKP6 (dual specific phosphatase 14) as a nonspecific regulatory molecule for delayed-type hypersensitivity. Br J Dermatol 2007; 156: 848-860, doi: 10.1111/j.1365-2133.2006.07708.x.
32. Maeda T, Kawane T, Horiuchi N. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology 2003; 144: 681-692, doi: 10.1210/en.2002-220682.
33. Maeda T, Matsunuma A, Kawane T, Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 2001; 280: 874-877, doi: 10.1006/bbrc.2000.4232.
34. Lian JB, Stein G.S. Concepts of osteoblast growth and differentiation: basis for modulation of bone cell development and tissue formation. Crit Rev Oral Biol Med 1992; 3: 269-305.
35. Lauder JM, Wilkie MB, Wu C, Singh S. Expression of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors in the mouse embryo. Int J Dev Neurosci 2000; 18: 653-662, doi: 10.1016/S0736-5748(00)00032-0.
36. Pakala R, Willerson JT, Benedict C.R. Mitogenic effect of serotonin on vascular endothelial cells. Circulation 1994; 90: 1919-1926, doi: 10.1161/01.CIR.90.4.1919.
37. Stroebel M, Goppelt-Struebe M. Signal transduction pathways responsible for serotonin-mediated prostaglandin G/H synthase expression in rat mesangial cells. J Biol Chem 1994; 269: 22952-22957.
38. Kode A, Mosialou I, Silva BC, Rached MT, Zhou B, Wang J, et al. FOXO1 orchestrates the bone-suppressing function of gut-derived serotonin. J Clin Invest 2012; 122: 3490-3503, doi: 10.1172/JCI64906.
39. Datta NS, Abou-Samra A.B. PTH and PTHrP signaling in osteoblasts. Cell Signal 2009; 21: 1245-1254, doi: 10.1016/j.cellsig.2009.02.012.